Treatment Satisfaction with Daclizumab in the Extend Study

Background: Patients’ treatment satisfaction is associated with improved medication adherence, which is critical for achieving successful treatment outcomes in chronic diseases such as multiple sclerosis (MS). The Treatment Satisfaction Questionnaire for Medication (TSQM) is a validated measure of treatment satisfaction.

Objectives: To assess treatment satisfaction with daclizumab HYP (daclizumab), a structurally distinct form of daclizumab, in patients with relapsing-remitting MS in an interim analysis of EXTEND, an ongoing, open-label long-term extension study of DECIDE.

Methods: In EXTEND, patients treated with intramuscular (IM) interferon (IFN) beta-1a or daclizumab in DECIDE receive daclizumab 150mg subcutaneous every 4 weeks for up to an additional 5 years. Patients completed the TSQM (version II) at baseline (following first dose of daclizumab) and at weeks 12, 24, 48, and 72. Data were collected through Jan 13, 2016 (patients enrolled in pre-filled pen [PFP] substudy) or Sep 10, 2015 (non-PFP patients).

Results: At the time of this analysis, the intention-to-treat population of EXTEND included 597 patients who switched from IM IFN beta-1a in DECIDE to daclizumab (IFN/DAC) and 606 patients who continued daclizumab treatment (DAC/DAC). At EXTEND baseline, for TSQM question 11 (“Taking all things into account, how satisfied or dissatisfied are you with this medication?”), 73.3% and 87.7% of patients reported being satisfied, very satisfied, or extremely satisfied, and 20.0% and 10.6% reported being somewhat satisfied with treatment, in the IFN/DAC (n=576) and DAC/DAC (n=587) groups, respectively. For the same question after 72 weeks of treatment with daclizumab in EXTEND, 85.5% and 90.6% reported being satisfied, very satisfied, or extremely satisfied, and 11.6% and 8.2% reported being somewhat satisfied with treatment, in the IFN/DAC (n=475) and DAC/DAC (n=449) groups, respectively.

Conclusions: High levels of satisfaction were maintained in the vast majority of patients during long-term treatment with daclizumab in the first 72 weeks of EXTEND. Treatment satisfaction in patients who switched from IM IFN beta-1a in DECIDE to daclizumab in EXTEND was lower at baseline but improved to levels similar to patients continuously-treated with daclizumab by week 72 of EXTEND.